689 related articles for article (PubMed ID: 36877351)
1. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
Zhu J; Wu T; Lin Q
Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
[TBL] [Abstract][Full Text] [Related]
2. An overview of signaling pathways regulating YAP/TAZ activity.
Heng BC; Zhang X; Aubel D; Bai Y; Li X; Wei Y; Fussenegger M; Deng X
Cell Mol Life Sci; 2021 Jan; 78(2):497-512. PubMed ID: 32748155
[TBL] [Abstract][Full Text] [Related]
3. New insights into the ambivalent role of YAP/TAZ in human cancers.
Luo J; Deng L; Zou H; Guo Y; Tong T; Huang M; Ling G; Li P
J Exp Clin Cancer Res; 2023 May; 42(1):130. PubMed ID: 37211598
[TBL] [Abstract][Full Text] [Related]
4. Hippo Signaling in the Liver Regulates Organ Size, Cell Fate, and Carcinogenesis.
Patel SH; Camargo FD; Yimlamai D
Gastroenterology; 2017 Feb; 152(3):533-545. PubMed ID: 28003097
[TBL] [Abstract][Full Text] [Related]
5. YAP/TAZ for cancer therapy: opportunities and challenges (review).
Guo L; Teng L
Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
[TBL] [Abstract][Full Text] [Related]
6. Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies.
Kim MH; Kim J
Cell Mol Life Sci; 2017 Apr; 74(8):1457-1474. PubMed ID: 27826640
[TBL] [Abstract][Full Text] [Related]
7. TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells.
Finch-Edmondson ML; Strauss RP; Passman AM; Sudol M; Yeoh GC; Callus BA
J Biol Chem; 2015 Nov; 290(46):27928-38. PubMed ID: 26432639
[TBL] [Abstract][Full Text] [Related]
8. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis.
Nishina H
Cancer Sci; 2022 Jun; 113(6):1900-1908. PubMed ID: 35349740
[TBL] [Abstract][Full Text] [Related]
9. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
Jang JW; Kim MK; Bae SC
Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
[TBL] [Abstract][Full Text] [Related]
10. YAP/TAZ at the Roots of Cancer.
Zanconato F; Cordenonsi M; Piccolo S
Cancer Cell; 2016 Jun; 29(6):783-803. PubMed ID: 27300434
[TBL] [Abstract][Full Text] [Related]
11. The Hippo Pathway in Prostate Cancer.
Salem O; Hansen CG
Cells; 2019 Apr; 8(4):. PubMed ID: 31018586
[TBL] [Abstract][Full Text] [Related]
12. RAP2 mediates mechanoresponses of the Hippo pathway.
Meng Z; Qiu Y; Lin KC; Kumar A; Placone JK; Fang C; Wang KC; Lu S; Pan M; Hong AW; Moroishi T; Luo M; Plouffe SW; Diao Y; Ye Z; Park HW; Wang X; Yu FX; Chien S; Wang CY; Ren B; Engler AJ; Guan KL
Nature; 2018 Aug; 560(7720):655-660. PubMed ID: 30135582
[TBL] [Abstract][Full Text] [Related]
13. Roles of YAP/TAZ in ferroptosis.
Magesh S; Cai D
Trends Cell Biol; 2022 Sep; 32(9):729-732. PubMed ID: 35701310
[TBL] [Abstract][Full Text] [Related]
14. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells.
Slaninová V; Heron-Milhavet L; Robin M; Jeanson L; Aissanou A; Kantar D; Tosi D; Bréhélin L; Gongora C; Djiane A
BMC Cancer; 2024 May; 24(1):587. PubMed ID: 38741073
[TBL] [Abstract][Full Text] [Related]
15. HERC3 promotes YAP/TAZ stability and tumorigenesis independently of its ubiquitin ligase activity.
Yuan B; Liu J; Shi A; Cao J; Yu Y; Zhu Y; Zhang C; Qiu Y; Luo H; Shi J; Cao X; Xu P; Shen L; Liang T; Zhao B; Feng XH
EMBO J; 2023 Feb; 42(4):e111549. PubMed ID: 36598329
[TBL] [Abstract][Full Text] [Related]
16. The emerging roles of YAP and TAZ in cancer.
Moroishi T; Hansen CG; Guan KL
Nat Rev Cancer; 2015 Feb; 15(2):73-79. PubMed ID: 25592648
[TBL] [Abstract][Full Text] [Related]
17. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer.
Jung O; Baek MJ; Wooldrik C; Johnson KR; Fisher KW; Lou J; Ricks TJ; Wen T; Best MD; Cryns VL; Anderson RA; Choi S
EMBO J; 2024 May; 43(9):1740-1769. PubMed ID: 38565949
[TBL] [Abstract][Full Text] [Related]
18. Non-secreting pituitary tumours characterised by enhanced expression of YAP/TAZ.
Xekouki P; Lodge EJ; Matschke J; Santambrogio A; Apps JR; Sharif A; Jacques TS; Aylwin S; Prevot V; Li R; Flitsch J; Bornstein SR; Theodoropoulou M; Andoniadou CL
Endocr Relat Cancer; 2019 Jan; 26(1):215-225. PubMed ID: 30139767
[TBL] [Abstract][Full Text] [Related]
19. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
[TBL] [Abstract][Full Text] [Related]
20. TAZ/YAP fusion proteins: mechanistic insights and therapeutic opportunities.
Garcia K; Gingras AC; Harvey KF; Tanas MR
Trends Cancer; 2022 Dec; 8(12):1033-1045. PubMed ID: 36096997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
